UK Drug Update - July 2003

Published: 1-Jul-2003
Regulatory


Mayne Pharma has made available 50mg, 150mg and 200mg capsules of the antifungal agent fluconazole.

Transdermal has brought out Dandrazol shampoo containing 2% of the antifungal agent ketoconazole.

Alpharma has introduced 50mg, 150mg and 200mg capsules of the antifungal agent fluconazole.

Merck Sharp & Dohme Ltd has marketed Ezetrol tablets. The tablets contain 10mg of the cholesterol absorption inhibitor ezetimibe.

Amgen has introduced Migard tablets containing 2.5mg of the selective 5HT1-receptor agonist frovatriptan. The company has also brought out Neulasta injection containing 6mg of the human granulocyte colony stimulating factor pegfilgrastim.

Wyeth Pharmaceuticals has launched Rapamune tablets containing 2mg of the immunosuppressant sirolimus.

Dermal Laboratories has marketed Nicam, a 4% gel formulation of nicotinamide, part of the vitamin B group.

PLIVA Pharma has brought out 50mg, 150mg and 200mg capsules of the antifungal agent fluconazole.

See more

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

Read more
New SOLAR CEMNEX analyser offers advanced compliance and connectivity features

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  5. FDA makes groundbreaking decision to waive clinical efficiency studies for monoclonal antibody biosimilars The University of Illinois secured the first-ever FDA acceptance to waive clinical efficiency studies (CESs) for the biological drugs

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Signal Group launches MCERTS approved VOC emissions monitor

New SOLAR CEMNEX analyser offers advanced compliance and connectivity features
You need to be a subscriber to read this article.
Click here to find out more.
Packaging

Cloud labelling and serialisation: the new frontline of traceability in drug delivery

As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision

Partnership delivers compliance confidence, efficiency gains and reduced waste
Regulatory

New NICE thresholds: good news for rare disease drugs but process remains complex

Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
Manufacturing

Balancing innovation and accessibility in amino acid testing

Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Quality management during manufacturing changes: part I

Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
Subscribe now